checkAd
    Ironwood Pharmaceuticals Registered (A) Aktie
    6,1000
     
    EUR
    +3,39 %
    +0,2000 EUR
    Letzter Kurs 10.06.24 Tradegate
    6,0000
     
    EUR
    500 STK
    Geldkurs 15:17:33
    6,1500
     
    EUR
    485 STK
    Briefkurs 15:17:33
    ISIN: US46333X1081 · WKN: A0X789 · SYM: I76 · USA

    Neueste Nachrichten

    Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
    30.05.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
    21.05.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals Reports First Quarter 2024 Results
    09.05.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
    06.05.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024
    01.05.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
    25.04.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
    28.03.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 01.03.2024
    01.03.24 · wO Chartvergleich · Biotest
    Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
    29.02.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
    23.02.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
    15.02.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)
    Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
    01.02.24 · Business Wire (engl.) · Ironwood Pharmaceuticals Registered (A)